We are live on
!
Find out more
Iovance Biotherapeutics
IOVA
IOVA
251 hedge funds and large institutions have $4.98B invested in Iovance Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 98 increasing their positions, 77 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more call options, than puts
Call options by funds: $37.9M | Put options by funds: $18.9M
27% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 77
5.5% more ownership
Funds ownership: 101.41% → 106.9% (+5.5%)
7% less funds holding
Funds holding: 269 → 251 (-18)
28% less capital invested
Capital invested by funds: $6.9B → $4.98B (-$1.92B)
29% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 58
36% less funds holding in top 10
Funds holding in top 10: 11 → 7 (-4)
Holders
251
Holders Change
-18
Holders Change %
-6.69%
% of All Funds
4.41%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
41
Increased
98
Reduced
77
Closed
58
Calls
$37.9M
Puts
$18.9M
Net Calls
+$18.9M
Net Calls Change
-$23.1M
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$184M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$181M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$98.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$67.8M |
| 5 |
Goldman Sachs
New York
|
+$48.6M |
